Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Top U.S. lawmaker wants corporate tax loophole 'plugged now'

Tue, 22nd Jul 2014 16:56

(Adds Hatch comments, paragraphs 4-9)

By Kevin Drawbaugh

WASHINGTON, July 22 (Reuters) - Immediate government actionis needed to stop U.S. corporations from avoiding federal taxesby shifting their tax domiciles overseas through deals known asinversions, the head of the U.S. Senate Finance Committee saidon Tuesday.

Nine inversion deals have been agreed to this year bycompanies ranging from banana distributor Chiquita BrandsInternational Inc to drugmaker AbbVie Inc andmore are being considered. The transactions are setting a recordpace since the first inversion was done 32 years ago.

Washington is increasingly concerned about this. "Let's worktogether to immediately cool down the inversion fever ... Theinversion loophole needs to be plugged now," said DemocraticSenator Ron Wyden, finance committee chairman, at a hearing.

Several Democrats have offered bills to curb inversions,which let companies cut their taxes primarily by putting foreignearnings out of the reach of the Internal Revenue Service.

Wyden said his panel asked the chief executives of severalinverted companies to testify at the hearing on internationaltax law problems. "None accepted our invitations," he said.

No new anti-inversion law is likely to be approved as longas Republicans insist that such a step be accompanied by anoverhaul of the tax code, policy analysts said.

Utah Senator Orrin Hatch, the finance committee's topRepublican, said, "The ultimate answer to this problem - and theonly way to completely address the issue of inversions - is toreform our tax code.

"However, as I've also said publicly, there may be stepsthat Congress can take to at least partially address this issuein the interim ... Whatever approach we take, it should not beretroactive or punitive. And it should be revenue neutral."

Hatch said he does not support recent bills introduced byDemocrats.

A senior official from the U.S. Treasury Department,speaking to the committee, reiterated the Obama administration'scall for urgent action by Congress to implement a White Houseproposal to make inversions more difficult to do.

"Congress should pass legislation immediately with aneffective date of May 2014 to prevent companies from effectivelyrenouncing their citizenship to get out of paying taxes," saidRobert Stack, deputy assistant secretary at the Treasury.

"We are aware of many more inversions in the works rightnow," he added.

But the Republican-controlled U.S. House of Representativeswill not act on inversions "unless there's comprehensive taxreform, and that's dead for this year," said Greg Valliere,chief political strategist at Potomac Research Group.

Inversions are still rare, but they are becoming morecommon. Of the roughly 60 deals done since 1982, more than halfhave come in just the last six years, a Reuters review showed.

An inversion involves a U.S. corporation buying or settingup a smaller company abroad, then shifting its tax home base tothat company's country, which typically has lower tax rates thanin the United States. Such deals usually mean opening a smalloffice abroad for tax purposes, leaving major operations intact. (Editing by Tom Brown and David Gregorio)

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.